Success Stories: With Our Diligent Efforts a Chinese Assistant Research Professor Working in the Field of Pharmaceutical Chemistry with 2 Chinese Patents, Achieved Approval for Both NIW and EB-1A
Client’s Testimonial:
“It is a very good experience to prepare my case with all of you!”
On March 1st, 2022, we received another EB-1A (Alien of Extraordinary Ability) approval for an Assistant Research Professor in the Field of Pharmaceutical Chemistry (Approval Notice).
General Field: Pharmaceutical Chemistry
Position at the Time of Case Filing: Assistant Research Professor
Country of Origin: China
State of Residence at the Time of Filing: Missouri
Approval Notice Date: March 1st, 2022
Processing Time: 2 months, 2 days (Premium Processing Requested)
Case Summary:
“Considering the whole of [the client’s] contributions to pharmaceutical chemistry and numerous publications, all in a specialty of vital and growing importance, it is without question that he is a uniquely valuable expert to the United States and an asset to the American scientific community.”
“As a result of [the client’s] commendable research, impressive background, and his continued contributions to his field, he has established a reputation for himself as a pharmaceutical chemist in the top echelons of his field. I contend that the United States will continue to benefit from his work for many years to come.”
These statements were made by two of the many recommenders that our client, a Ph.D. in Pharmaceutical Chemistry from China was able to obtain for his EB-1A (Alien of Extraordinary Ability) petition at USCIS. Having had prior experience with the client while representing him for his NIW (National Interest Waiver) case, we were able to ascertain that his EB-1A petition had merit. We assured him that we will personalize his application and tailor it to fit the strict criteria set for the EB-1A category. As our client was already residing in the U.S.A. and fulfilled the job requirements working as an assistant research professor at one of the country’s universities, we made sure that his case was a success by including a detailed list of his academic publications, citations, and peer review experience along with information of funds and grants that he had received.
We already knew that he has many publications to his name. We thus made a list of all of them and the journals along with the impact factor that it generated. We found him to have published over 31 peer-reviewed scientific articles, and 1 book chapter. It aided our case to know that he had 2 Chinese patents to his name. His publications had also been cited by researchers in at least 39 countries according to Google Scholar, thereby demonstrating that these publications were widely recognized and relied upon. Due to its great applicability in the field, his research in pharmaceutical chemistry had been cited a total of 406 times in other peer-reviewed journal articles. The field has also recognized his authority by inviting him to review and evaluate the work of his peers no fewer than 36 times.
His study had received funding from 1 institute in China and 1 in the U.S. The National Science Foundation of China grant was given to him for supporting projects that do basic research, develop international cooperation, and promote socio-economic development. His study has also been supported by funding from the National Institutes of Health which finances projects that enhance life and reduce illness and disability. This support of his research, therefore, was evidence that his scholarship serves to advance the public health interests of the United States.
We were thus certain that his case would qualify for the strict EB-1A criteria which demands evidence of extraordinary ability. We are thankful to him for retaining us for his EB-1A application after our victory in his NIW case. We wish him the very best in life!